Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Naïve and newly debuted: configurations of the trial participant in phase II-III clinical trials
Luleå tekniska universitet, Institutionen för ekonomi, teknik och samhälle, Arbetsvetenskap.
2008 (engelsk)Inngår i: Society for Social Studies of Science, European Association for the Study of Science and Technology , 2008Konferansepaper, Meeting abstract (Annet vitenskapelig)
Abstract [en]

An increasingly large part of pharmaceutical testing is performed by contract research organisations (CROs). This development is a consequence of the pharmaceutical industry's need to speed up the trial process in order to get drugs out to the market quicker, as well as a result of tighter bureaucracy surrounding clinical trials. Tasks performed by CROs include faster screening and recruitment of test subjects, tasks that traditionally have been done by the clinics themselves. For Sweden and other European countries, such a change implies large scale privatisation of the work performed in clinical trials. This paper discusses the consequences of this privatisation for the configuration of trial participants.The paper focuses a few of these configurations through analysing the discourses of test subjects in and around contract research organizations as they emerge in one CROs promotional material, as well as in local newspapers' coverage of the company when it was established in a Swedish city in 2004. One of the tasks of the company, dealing with phase II-III trials, is to recruit "naïve" and "newly debuted" participants. This means finding individuals who fit the often narrow inclusion criteria for participating in the trial, but who do not (yet) know that they are "at risk". The multi-layered meanings of this terminology are discussed, and a potential consequence of the argumentation is investigated: a tendency that clinical trials are configured as part of prevention programmes on behalf of public health care practitioners. More broadly, the paper thus focuses how the biomedicalisation of health interrelate with drug testing practice/discourse; and health promotion and prevention initiatives.

sted, utgiver, år, opplag, sider
European Association for the Study of Science and Technology , 2008.
HSV kategori
Forskningsprogram
Genus och teknik
Identifikatorer
URN: urn:nbn:se:ltu:diva-27539Lokal ID: 108e1140-a040-11dd-8f4e-000ea68e967bOAI: oai:DiVA.org:ltu-27539DiVA, id: diva2:1000723
Konferanse
Acting with Science, Technology and Medicine : 20/08/2008 - 23/08/2008
Merknad
Godkänd; 2008; 20081022 (petjon)Tilgjengelig fra: 2016-09-30 Laget: 2016-09-30 Sist oppdatert: 2017-11-25bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Personposter BETA

Jonvallen, Petra

Søk i DiVA

Av forfatter/redaktør
Jonvallen, Petra
Av organisasjonen

Søk utenfor DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric

urn-nbn
Totalt: 3 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf